Dashboard / Ticker
RVMD · Revolution Medicines, Inc.Revolution Medicines, Inc.
🔬 Daraxonrasib (RVMD) shows near doubling of median overall survival in Phase 3 trial for pancreatic cancer vs chemo, with FDA expanded access and potential for regulatory filing, leading to platform value re-rating
high convictionFirst mentioned Jun 1, 2026
Daraxonrasib (RVMD) shows near doubling of median overall survival in Phase 3 trial for pancreatic cancer vs chemo, with FDA expanded access and potential for regulatory filing, leading to platform value re-rating.
Chart
Post Timeline · 0 posts
No posts found
Current Price
$155.69
via cornerstones
Return from entry
—
entry Jun 1, 2026
Thesis Lifecycle
🟢
openedJun 1, 2026
Daraxonrasib (RVMD) shows near doubling of median overall survival in Phase 3 trial for pancreatic cancer vs chemo, with FDA expanded access and potential for regulatory filing, leading to platform value re-rating.
source ↗